Metamorphosis of prostate specific membrane antigen (PSMA) inhibitors

[1]  H. Wester,et al.  Design of PSMA ligands with modifications at the inhibitor part: an approach to reduce the salivary gland uptake of radiolabeled PSMA inhibitors? , 2021, EJNMMI Radiopharmacy and Chemistry.

[2]  O. Bavi,et al.  Potential effective inhibitory compounds against Prostate Specific Membrane Antigen (PSMA): A molecular docking and molecular dynamics study. , 2021, Archives of biochemistry and biophysics.

[3]  P. Barata,et al.  PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy , 2020, Cancers.

[4]  P. Geramifar,et al.  Design, synthesis, radiolabeling and biological evaluation of new urea-based peptides targeting prostate specific membrane antigen. , 2020, Bioorganic chemistry.

[5]  U. Tateishi.  Prostate-specific membrane antigen (PSMA)–ligand positron emission tomography and radioligand therapy (RLT) of prostate cancer , 2020, Japanese journal of clinical oncology.

[6]  Christina Baun,et al.  Design, Synthesis, Computational, and Preclinical Evaluation of natTi/45Ti-Labeled Urea-Based Glutamate PSMA Ligand , 2020, Molecules.

[7]  Gideon Adamu Shallangwa,et al.  In-silico modelling studies on some C14-urea-tetrandrine derivatives as potent anti-cancer agents against prostate (PC3) cell line , 2020 .

[8]  A. Ciarmiello,et al.  Toward the Discovery and Development of PSMA Targeted Inhibitors for Nuclear Medicine Applications , 2020, Current radiopharmaceuticals.

[9]  H. Ahmadzadehfar,et al.  Historical review of pharmacological development and dosimetry of PSMA-based theranostics for prostate cancer , 2019, Journal of Radioanalytical and Nuclear Chemistry.

[10]  Anastasia V Aladinskaya,et al.  Synthesis and biological evaluation of PSMA-targeting paclitaxel conjugates. , 2019, Bioorganic & medicinal chemistry letters.

[11]  Anastasia V Aladinskaya,et al.  Synthesis and biological evaluation of Doxorubicin-containing conjugate targeting PSMA. , 2019, Bioorganic & medicinal chemistry letters.

[12]  N. Sharma,et al.  In silico identification of key genes and signaling pathways targeted by a panel of signature microRNAs in prostate cancer , 2019, Medical Oncology.

[13]  Kirsten L. Greene,et al.  Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer , 2018, The Journal of Nuclear Medicine.

[14]  M. Schwaiger,et al.  Synthesis and in vitro and in vivo evaluation of urea-based PSMA inhibitors with increased lipophilicity , 2018, EJNMMI Research.

[15]  F. Kobarfard,et al.  Novel and Efficient Method for Solid Phase Synthesis of Urea-Containing Peptides Targeting Prostate Specific Membrane Antigen (PSMA) in Comparison with Current Methods , 2018, Iranian journal of pharmaceutical research : IJPR.

[16]  N. Sharma,et al.  The microRNA signatures: aberrantly expressed miRNAs in prostate cancer , 2018, Clinical and Translational Oncology.

[17]  Amit Pandit,et al.  First report on 3D-QSAR and molecular dynamics based docking studies of GCPII inhibitors for targeted drug delivery applications , 2018 .

[18]  H. Kung,et al.  Synthesis and evaluation of a novel urea-based 68Ga-complex for imaging PSMA binding in tumor. , 2017, Nuclear medicine and biology.

[19]  Roger Slavik,et al.  PSMA ligands in prostate cancer - Probe optimization and theranostic applications. , 2017, Methods.

[20]  U. Haberkorn,et al.  Glu-Ureido–Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers , 2017, The Journal of Nuclear Medicine.

[21]  W. Heston,et al.  Should Low Molecular Weight PSMA Targeted Ligands Get Bigger and Use Albumin Ligands for PSMA Targeting? , 2017, Theranostics.

[22]  C. Anderson,et al.  177 Lu-Labeled Phosphoramidate-Based PSMA Inhibitors : The Effect of an Albumin Binder on Biodistribution and Therapeutic Efficacy in Prostate Tumor-Bearing Mice , 2017 .

[23]  V. Kutala,et al.  In silico approaches to identify the potential inhibitors of glutamate carboxypeptidase II (GCPII) for neuroprotection. , 2016, Journal of theoretical biology.

[24]  H. VanBrocklin,et al.  Structure-Activity Relationship of (18)F-Labeled Phosphoramidate Peptidomimetic Prostate-Specific Membrane Antigen (PSMA)-Targeted Inhibitor Analogues for PET Imaging of Prostate Cancer. , 2016, Journal of medicinal chemistry.

[25]  K. Pienta,et al.  PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges , 2016, Prostate Cancer and Prostatic Disease.

[26]  U. Haberkorn,et al.  Design of Internalizing PSMA-specific Glu-ureido-based Radiotherapeuticals , 2016, Theranostics.

[27]  J. Vávra,et al.  Unprecedented Binding Mode of Hydroxamate-Based Inhibitors of Glutamate Carboxypeptidase II: Structural Characterization and Biological Activity. , 2016, Journal of medicinal chemistry.

[28]  Anastasia V Aladinskaya,et al.  Small-molecule PSMA ligands. Current state, SAR and perspectives , 2016, Journal of drug targeting.

[29]  M. Pomper,et al.  [(18)F]Fluorobenzoyllysinepentanedioic Acid Carbamates: New Scaffolds for Positron Emission Tomography (PET) Imaging of Prostate-Specific Membrane Antigen (PSMA). , 2016, Journal of medicinal chemistry.

[30]  J. Lubkowski,et al.  Design of composite inhibitors targeting glutamate carboxypeptidase II: the importance of effector functionalities , 2016, The FEBS journal.

[31]  M. Pomper,et al.  Prostate-specific membrane antigen as a target for cancer imaging and therapy. , 2015, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[32]  J. Konvalinka,et al.  Structural and biochemical characterization of the folyl‐poly‐γ‐l‐glutamate hydrolyzing activity of human glutamate carboxypeptidase II , 2014, The FEBS journal.

[33]  D. Ferraris,et al.  δ-Thiolactones as prodrugs of thiol-based glutamate carboxypeptidase II (GCPII) inhibitors. , 2014, Journal of medicinal chemistry.

[34]  Martin G Pomper,et al.  PET imaging in prostate cancer: focus on prostate-specific membrane antigen. , 2013, Current topics in medicinal chemistry.

[35]  Paul D Benny,et al.  PSMA‐targeted SPECT agents: Mode of binding effect on in vitro performance , 2013, The Prostate.

[36]  U. Haberkorn,et al.  A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer , 2012, EJNMMI Research.

[37]  J. Bryan,et al.  A phosphoramidate‐based prostate‐specific membrane antigen‐targeted SPECT agent , 2012, The Prostate.

[38]  U. Haberkorn,et al.  68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. , 2012, Bioconjugate chemistry.

[39]  J. Konvalinka,et al.  Efficient and versatile one-step affinity purification of in vivo biotinylated proteins: expression, characterization and structure analysis of recombinant human glutamate carboxypeptidase II. , 2012, Protein expression and purification.

[40]  D. Ferraris,et al.  Structure-activity relationships of glutamate carboxypeptidase II (GCPII) inhibitors. , 2012, Current medicinal chemistry.

[41]  Steve Y. Cho,et al.  GCPII imaging and cancer. , 2012, Current medicinal chemistry.

[42]  M. Pomper,et al.  Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer. , 2012, Current medicinal chemistry.

[43]  J. Konvalinka,et al.  Chapter 3:Glutamate Carboxypeptidase II as a Therapeutic Target , 2011 .

[44]  M. Pomper,et al.  Novel substrate-based inhibitors of human glutamate carboxypeptidase II with enhanced lipophilicity. , 2011, Journal of medicinal chemistry.

[45]  J. McNamara,et al.  Rational truncation of an RNA aptamer to prostate-specific membrane antigen using computational structural modeling. , 2011, Nucleic acid therapeutics.

[46]  Yuko Fujita,et al.  Orally active glutamate carboxypeptidase II inhibitor 2-MPPA attenuates dizocilpine-induced prepulse inhibition deficits in mice , 2011, Brain Research.

[47]  Tiancheng Liu,et al.  A targeted low molecular weight near-infrared fluorescent probe for prostate cancer. , 2010, Bioorganic & medicinal chemistry letters.

[48]  R. Pfragner,et al.  BASIC SCIENCE REVIEW , 2010 .

[49]  W. L. Jorgensen,et al.  A remote arene-binding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules. , 2010, Journal of the American Chemical Society.

[50]  F. Schuber,et al.  Identification of the N-glycosylation sites on recombinant bovine CD38 expressed in Pichia pastoris: their impact on enzyme stability and catalytic activity. , 2010, Protein expression and purification.

[51]  M. Pomper,et al.  Bioisosterism of urea-based GCPII inhibitors: Synthesis and structure-activity relationship studies. , 2010, Bioorganic & medicinal chemistry letters.

[52]  H. VanBrocklin,et al.  Assessment of an 18F-Labeled Phosphoramidate Peptidomimetic as a New Prostate-Specific Membrane Antigen–Targeted Imaging Agent for Prostate Cancer , 2009, Journal of Nuclear Medicine.

[53]  J. Konvalinka,et al.  Reaction mechanism of glutamate carboxypeptidase II revealed by mutagenesis, X-ray crystallography, and computational methods. , 2009, Biochemistry.

[54]  M. Pomper,et al.  Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. , 2008, Journal of medicinal chemistry.

[55]  Tiancheng Liu,et al.  Pseudoirreversible inhibition of prostate-specific membrane antigen by phosphoramidate peptidomimetics. , 2008, Biochemistry.

[56]  M. Pomper,et al.  Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization. , 2008, Journal of medicinal chemistry.

[57]  Tiancheng Liu,et al.  Cell‐Surface labeling and internalization by a fluorescent inhibitor of prostate‐specific membrane antigen , 2008, The Prostate.

[58]  Martin G. Pomper,et al.  Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA) , 2008, Cancer biology & therapy.

[59]  J. Konvalinka,et al.  Structural basis of interactions between human glutamate carboxypeptidase II and its substrate analogs. , 2008, Journal of molecular biology.

[60]  Marc O. Anderson,et al.  Phosphoramidate derivatives of hydroxysteroids as inhibitors of prostate-specific membrane antigen. , 2008, Bioorganic & medicinal chemistry letters.

[61]  Cheryl A. Tajon,et al.  The molecular pruning of a phosphoramidate peptidomimetic inhibitor of prostate-specific membrane antigen. , 2007, Bioorganic & medicinal chemistry.

[62]  J. Konvalinka,et al.  Mapping of the active site of glutamate carboxypeptidase II by site‐directed mutagenesis , 2007, The FEBS journal.

[63]  J. Konvalinka,et al.  Structural insight into the pharmacophore pocket of human glutamate carboxypeptidase II. , 2007, Journal of medicinal chemistry.

[64]  Rolf Hilgenfeld,et al.  Human glutamate carboxypeptidase II inhibition: structures of GCPII in complex with two potent inhibitors, quisqualate and 2-PMPA. , 2007, Acta crystallographica. Section D, Biological crystallography.

[65]  A. Sima,et al.  The preventive and therapeutic effects of GCPII (NAALADase) inhibition on painful and sensory diabetic neuropathy , 2006, Journal of the Neurological Sciences.

[66]  J. Konvalinka,et al.  Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer , 2006, The EMBO journal.

[67]  J. Neale,et al.  NAAG peptidase inhibitors and their potential for diagnosis and therapy , 2005, Nature Reviews Drug Discovery.

[68]  D. Hilt,et al.  The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693. , 2005, British journal of clinical pharmacology.

[69]  M. Pomper,et al.  Radiolabeled Small-Molecule Ligands for Prostate-Specific Membrane Antigen: In vivo Imaging in Experimental Models of Prostate Cancer , 2005, Clinical Cancer Research.

[70]  Seung-Yong Jeong,et al.  Metabotropic Glutamate Receptor 4 Expression in Colorectal Carcinoma and Its Prognostic Significance , 2005, Clinical Cancer Research.

[71]  Mindy I. Davis,et al.  Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[72]  M. Koutsilieris,et al.  Characterization of the glutametergic system in MG-63 osteoblast-like osteosarcoma cells. , 2004, Anticancer research.

[73]  C. Berkman,et al.  Probing for a hydrophobic a binding register in prostate-specific membrane antigen with phenylalkylphosphonamidates. , 2004, Bioorganic & medicinal chemistry.

[74]  J. Konvalinka,et al.  Identification of the N‐glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity , 2004, Protein science : a publication of the Protein Society.

[75]  J. Neale,et al.  Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents. , 2004, Journal of medicinal chemistry.

[76]  A. Bodner,et al.  Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[77]  Monicia R. Hall,et al.  Synthesis and biological evaluation of hydroxamate-Based inhibitors of glutamate carboxypeptidase II. , 2003, Bioorganic & medicinal chemistry letters.

[78]  Qun Liu,et al.  Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor. , 2003, Journal of medicinal chemistry.

[79]  J. Konvalinka,et al.  Substrate specificity, inhibition and enzymological analysis of recombinant human glutamate carboxypeptidase II , 2002, Journal of neurochemistry.

[80]  X. C. Lu,et al.  Design and pharmacological activity of phosphinic acid based NAALADase inhibitors. , 2001, Journal of medicinal chemistry.

[81]  J. Neale,et al.  Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase). , 2001, Journal of medicinal chemistry.

[82]  L. E. Ross,et al.  Design, synthesis, and biological activity of a potent inhibitor of the neuropeptidase N-acetylated alpha-linked acidic dipeptidase. , 1996, Journal of medicinal chemistry.

[83]  W. Fair,et al.  Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. , 1995, Cancer research.

[84]  P. Schellhammer,et al.  Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. , 1995, Urologic oncology.

[85]  J. Coyle,et al.  Hydrolysis of the brain dipeptide N-acetyl-L-aspartyl-L-glutamate. Identification and characterization of a novel N-acetylated alpha-linked acidic dipeptidase activity from rat brain. , 1987, The Journal of biological chemistry.